Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
Blood Cancer J
.
2020 Jul 24;10(7):77.
doi: 10.1038/s41408-020-00342-x.
Authors
Franco Locatelli
1
,
Gerhard Zugmaier
2
,
Noemi Mergen
3
,
Peter Bader
4
,
Sima Jeha
5
,
Paul-Gerhardt Schlegel
6
,
Jean-Pierre Bourquin
7
,
Rupert Handgretinger
8
,
Benoit Brethon
9
,
Claudia Rossig
10
,
Christiane Chen-Santel
11
Affiliations
1
Department of Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Sapienza, University of Rome, Rome, Italy.
2
Amgen Research (Munich) GmbH, Munich, Germany. gerhardz@amgen.com.
3
Amgen Research (Munich) GmbH, Munich, Germany.
4
Department for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany.
5
St Jude Children's Research Hospital, Memphis, TN, USA.
6
University Children's Hospital Wuerzburg, Wuerzburg, Germany.
7
Department of Pediatric Oncology, Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland.
8
Department of Hematology/Oncology, University Children's Hospital Tuebingen, Tuebingen, Germany.
9
Pediatric Hematology and Immunology Department, Robert Debre Hospital, APHP, Paris, France.
10
Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
11
Department of Pediatrics, Division of Oncology and Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany.
PMID:
32709851
PMCID:
PMC7381625
DOI:
10.1038/s41408-020-00342-x
No abstract available
Publication types
Letter